Basilea posts revenue €118.37M, 31% up from last year

Basilea Pharmaceutica posted preliminary revenue for the financial year 2018, which is expected to increase by 31% over 2017 to about CHF133 million (€118.37M), from the last year’s CHF101.5 million (€90.3M).

The company on monday said that it had about CHF 82 million, or 56% more compared to last yera, from sales of its two products, the antifungal Cresemba and the antibiotic Zevtera. Basilea had guided for total revenue of CHF 120-130 million and contributions from Cresemba and Zevtera of CHF 75-85 million for the financial year 2018, it said in the announcement.

David Veitch, Chief Executive Officer of Basilea said: “The increase of 56% in the revenue contributions from our two marketed products, Cresemba and Zevtera, confirms in particular the continued strong sales ramp-up of Cresemba, both in established markets and the more recently launched markets. Against the background of the continued high unmet medical need of patients suffering from invasive mold infections and the significant number of upcoming country launches, we are very positive for the future sales prospects of the brand.”